CCNE2 and cancer: While eravacycline and omadacycline have never been tested for their potential anti-cancer activity, tigecycline, which was approved as an antibiotic in 2005 [13, 14], demonstrated possible anti-cancer activity and, in the case of PDAC, exerted its action via downregulating of CCNE2 [15].